Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 4/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126116 | 0.87 | CTSS (0.47) | CTSSCTSKUSP2SMN1; SMN2CTSL | |
| SCHEMBL5123159 | 0.84 | CTSS (0.51) | CTSSCTSKCTSL | |
| SCHEMBL8289728 | 0.79 | CTSS (0.48) | CTSSCTSKUSP2SMN1; SMN2CTSL | |
| SCHEMBL5122570 | 0.72 | CTSS (0.49) | CTSSCTSKCTSLCTSBCYP3A4 | |
| SCHEMBL3741937 | 0.72 | CTSK (0.50) | CTSSCTSKUSP2SMN1; SMN2CTSL | |
| SCHEMBL5132638 | 0.72 | CTSS (0.50) | CTSSCTSKCTSL | |
| SCHEMBL24214307 | 0.71 | CTSK (0.47) | CTSSCTSKCTSLCTSBCYP2C19 | |
| SCHEMBL6296123 | 0.71 | CTSK (0.47) | CTSSCTSKCTSLCTSBCYP2C19 | |
| SCHEMBL1343403 | 0.71 | CTSK (0.47) | CTSSCTSKCTSLCTSBCYP2C19 | |
| SCHEMBL13044376 | 0.71 | CTSK (0.47) | CTSSCTSKUSP2SMN1; SMN2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | LIU HONG | 2008-01-24 | — | — | US | disclosed |
| US-7297714-B2 | Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid | IRM LLC (BM) | 2007-11-20 | — | — | US | disclosed |
| US-20050130959-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885USP2 553/4885 |
| US-20050130959-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885USP2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.